Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Abstract LB405: CTP synthase 1 is a synthetic vulnerability in prostate cancer treated with supraphysiological androgen

Sheila Jonnatan, Rajendra Kumar, Varsha Vakkala, Karthik Vasan, Zachary R. Chalmers, Daniel R. Schmidt, Philip A. Beer, Matthew G. Vander Heiden, Samuel R. Denmeade, Navdeep S. Chandel, Laura A. Sena

Cancer Res (2024) 84 (7_Supplement): LB405.

https://doi.org/10.1158/1538-7445.AM2024-LB405

Published: 05 April 2024

View articletitled, Abstract LB405: CTP synthase 1 is a synthetic vulnerability in prostate cancer treated with supraphysiological androgen

Journal Articles

Abstract 3232: LSD1 inhibition transcriptionally reprograms neuroendocrine prostate cancer exposing unique therapeutic vulnerabilities

Sumer M. Jasmine, Adel Mandl, Susan L. Dalrymple, Sunghyun Kim, Jennifer Dias, Maria Kleppe, Cassandra Celatka, Amy Tapper, Ilsa Coleman, Peter Nelson, Hugh Rienhoff, Samuel R. Denmeade, W. Nathaniel Brennen

Cancer Res (2024) 84 (6_Supplement): 3232.

https://doi.org/10.1158/1538-7445.AM2024-3232

Published: 22 March 2024

View articletitled, Abstract 3232: LSD1 inhibition transcriptionally reprograms neuroendocrine prostate cancer exposing unique therapeutic vulnerabilities

Journal Articles

Abstract 6055: Cell confluence growth tracking as a supplement assay for clonogenic assay in prostate cancer radiotherapy combination evaluation

Wen Jiang, W. Nathaniel Brennen, Samuel R. Denmeade, Daniel L. Thorek

Cancer Res (2022) 82 (12_Supplement): 6055.

https://doi.org/10.1158/1538-7445.AM2022-6055

Published: 15 June 2022

View articletitled, Abstract 6055: Cell confluence growth tracking as a supplement assay for clonogenic assay in prostate cancer radiotherapy combination evaluation

Journal Articles

Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer

Cancer Res (2021) 81 (23): 5948–5962.

https://doi.org/10.1158/0008-5472.CAN-20-3607

Published: 01 December 2021

View articletitled, Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer

Includes: Supplementary data

Journal Articles

Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?

Laura A. Sena, Samuel R. Denmeade

Cancer Res (2021) 81 (17): 4385–4393.

https://doi.org/10.1158/0008-5472.CAN-21-1392

Published: 01 September 2021

View articletitled, Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?

Journal Articles

Abstract 2404: Increased mitochondrial DNA copy number occurs during prostate cancer progression and in cancer precursor lesions across multiple organs

Jiayu Chen, Qizhi Zheng, Jessica L. Hicks, Levent Trabzonlu, Emmanuel S. Antonarakis, Mark C. Markowski, Samuel R. Denmeade, Busra Ozbek, Anuj Gupta, Tatianna C. Larman, Ralph H. Hruban, Sarah Wheelan, Srinivasan Yegnasubramanian, Angelo M. De Marzo

Cancer Res (2021) 81 (13_Supplement): 2404.

https://doi.org/10.1158/1538-7445.AM2021-2404

Published: 01 July 2021

View articletitled, Abstract 2404: Increased mitochondrial DNA copy number occurs during prostate cancer progression and in cancer precursor lesions across multiple organs

Journal Articles

Abstract 85: CCAAT/enhancer binding protein beta facilitates castrate-resistant prostate cancer cell growth and sensitivity to mTOR inhibitors

David J. Barakat, Jing Zhang, Alan D. Friedman, Samuel R. Denmeade, Ido Paz-Priel

Cancer Res (2015) 75 (15_Supplement): 85.

https://doi.org/10.1158/1538-7445.AM2015-85

Published: 01 August 2015

View articletitled, Abstract 85: CCAAT/enhancer binding protein beta facilitates castrate-resistant prostate cancer cell growth and sensitivity to mTOR inhibitors

Journal Articles

Abstract 2910: Androgen receptor splice variant-7 predicts resistance to enzalutamide in patients with castration-resistant prostate cancer

Emmanuel S. Antonarakis, Changxue Lu, Hao Wang, Brandon Luber, Mary Nakazawa, Jeffrey C. Roeser, Yan Chen, Helen L. Fedor, Tamara L. Lotan, Angelo M. De Marzo, John T. Isaacs, William B. Isaacs, Rosa Nadal, Channing J. Paller, Samuel R. Denmeade, Michael A. Carducci, Mario A. Eisenberger, Jun Luo

Cancer Res (2014) 74 (19_Supplement): 2910.

https://doi.org/10.1158/1538-7445.AM2014-2910

Published: 01 October 2014

View articletitled, Abstract 2910: Androgen receptor splice variant-7 predicts resistance to enzalutamide in patients with castration-resistant prostate cancer

Journal Articles

Abstract B21: Mesenchymal stem cells (MSCs) as a selective delivery vehicle for a PSA-activated protoxin for advanced prostate cancer

W. Nathaniel Brennen, Samuel R. Denmeade, John T. Isaacs

Cancer Res (2012) 72 (4_Supplement): B21.

https://doi.org/10.1158/1538-7445.PRCA2012-B21

Published: 09 May 2013

View articletitled, Abstract B21: Mesenchymal stem cells (MSCs) as a selective delivery vehicle for a PSA-activated protoxin for advanced prostate cancer

Journal Articles

Abstract 5058: Expansion and validation of the prostate-specific antigen substrate degradome.

Sangmi Nam, Niquiche Sangster-Guity, Theodore E. Ewachiw, Samuel R. Denmeade, Simon A. Williams

Cancer Res (2013) 73 (8_Supplement): 5058.

https://doi.org/10.1158/1538-7445.AM2013-5058

Published: 15 April 2013

View articletitled, Abstract 5058: Expansion and validation of the prostate-specific antigen substrate degradome.

Journal Articles

Abstract 5699: Mesenchymal stem cells (MSCs) as a selective delivery vehicle for a PSA-activated protoxin for advanced prostate cancer

Shuangling Chen, Nathaniel Brennen, Robert A. Brodsky, Linzhao Cheng, Samuel R. Denmeade, John T. Isaacs

Cancer Res (2012) 72 (8_Supplement): 5699.

https://doi.org/10.1158/1538-7445.AM2012-5699

Published: 15 April 2012

View articletitled, Abstract 5699: Mesenchymal stem cells (MSCs) as a selective delivery vehicle for a PSA-activated protoxin for advanced prostate cancer

Journal Articles

Abstract 1424: Fibroblast activation protein alpha (FAP): Targeting the reactive stroma as a novel prodrug therapy

William N. Brennen, Marc Rosen, Samuel R. Denmeade

Cancer Res (2010) 70 (8_Supplement): 1424.

https://doi.org/10.1158/1538-7445.AM10-1424

Published: 15 April 2010

View articletitled, Abstract 1424: Fibroblast activation protein alpha (FAP): Targeting the reactive stroma as a novel prodrug therapy

Journal Articles

Abstract 2326: Loss of prostate-specific antigen slows growth and alters the extracellular proteome of LNCaP human prostate cancer cells

Simon A. Williams, Christine A. Jelinek, Robert J. Cotter, John T. Isaacs, Samuel R. Denmeade

Cancer Res (2010) 70 (8_Supplement): 2326.

https://doi.org/10.1158/1538-7445.AM10-2326

Published: 15 April 2010

View articletitled, Abstract 2326: Loss of prostate-specific antigen slows growth and alters the extracellular proteome of LNCaP human prostate cancer cells

Journal Articles

A Dimeric Peptide That Binds Selectively to Prostate-Specific Membrane Antigen and Inhibits its Enzymatic Activity

Saurabh Aggarwal, Pratap Singh, Ozlem Topaloglu, John T. Isaacs, Samuel R. Denmeade

Cancer Res (2006) 66 (18): 9171–9177.

https://doi.org/10.1158/0008-5472.CAN-06-1520

Published: 18 September 2006

View articletitled, A Dimeric Peptide That Binds Selectively to Prostate-Specific Membrane Antigen and Inhibits its Enzymatic Activity

Journal Articles

Prostate-Specific Membrane Antigen (PSMA) targeted prodrug “smartbombs” as therapy for prostate cancer

Annastasiah Mhaka, Pratap Singh, Marc Rosen, Craig A. Dionne, Soeren B. Christensen, John T. Isaacs, Samuel R. Denmeade

Cancer Res (2006) 66 (8_Supplement): 725.

Published: 15 April 2006

View articletitled, Prostate-Specific Membrane Antigen (PSMA) targeted prodrug “smartbombs” as therapy for prostate cancer

Journal Articles

Development and characterization of prostate specific antigen inhibitors

Simon A. Williams, Meha H. Shah, Pratap Singh, Ciby J. Abraham, Aaron Lebeau, Thomas Lectka, Samuel R. Denmeade

Cancer Res (2006) 66 (8_Supplement): 1028–1029.

Published: 15 April 2006

View articletitled, Development and characterization of prostate specific antigen inhibitors

Journal Articles

PSA-activated proaerolysin as a prostate specific cancer therapy

Jeff L. Browning, Ralph Abi-Habib, Ravibhushan Singh, Carol Carter, Janelle Ortiz, Rosemina Merchant, J. Thomas Buckley, Samuel R. Denmeade, Arthur E. Frankel

Cancer Res (2006) 66 (8_Supplement): 514.

Published: 15 April 2006

View articletitled, PSA-activated proaerolysin as a prostate specific cancer therapy

Journal Articles

Tumoricidal effects of a PSA-activated pore-forming toxin

Simon A. Williams, J. Thomas Buckley, Samuel R. Denmeade

Cancer Res (2005) 65 (9_Supplement): 1446.

Published: 01 May 2005

View articletitled, Tumoricidal effects of a PSA-activated pore-forming toxin

Journal Articles

Prostate Specific Membrane Antigen (PSMA): A prodrug target for prostate cancer

Annastasiah M. Mhaka, Samuel Janssen, John T. Isaacs, Samuel R. Denmeade

Cancer Res (2004) 64 (7_Supplement): 145.

Published: 01 April 2004

View articletitled, Prostate Specific Membrane Antigen (PSMA): A prodrug target for prostate cancer

Journal Articles

Nanoparticles as novel vectors for targeted drug delivery to prostate cancer

Srinivas K. Kumar, Indarjit Roy, Samuel R. Denmeade, John T. Isaacs, Anirban Maitra, Saeed R. Khan

Cancer Res (2004) 64 (7_Supplement): 150.

Published: 01 April 2004

View articletitled, Nanoparticles as novel vectors for targeted drug delivery to prostate cancer

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract LB405: CTP synthase 1 is a synthetic vulnerability in prostate cancer treated with supraphysiological androgen

Abstract 3232: LSD1 inhibition transcriptionally reprograms neuroendocrine prostate cancer exposing unique therapeutic vulnerabilities

Abstract 6055: Cell confluence growth tracking as a supplement assay for clonogenic assay in prostate cancer radiotherapy combination evaluation

Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer

Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?

Abstract 2404: Increased mitochondrial DNA copy number occurs during prostate cancer progression and in cancer precursor lesions across multiple organs

Abstract 85: CCAAT/enhancer binding protein beta facilitates castrate-resistant prostate cancer cell growth and sensitivity to mTOR inhibitors

Abstract 2910: Androgen receptor splice variant-7 predicts resistance to enzalutamide in patients with castration-resistant prostate cancer

Abstract B21: Mesenchymal stem cells (MSCs) as a selective delivery vehicle for a PSA-activated protoxin for advanced prostate cancer

Abstract 5058: Expansion and validation of the prostate-specific antigen substrate degradome.

Abstract 5699: Mesenchymal stem cells (MSCs) as a selective delivery vehicle for a PSA-activated protoxin for advanced prostate cancer

Abstract 1424: Fibroblast activation protein alpha (FAP): Targeting the reactive stroma as a novel prodrug therapy

Abstract 2326: Loss of prostate-specific antigen slows growth and alters the extracellular proteome of LNCaP human prostate cancer cells

A Dimeric Peptide That Binds Selectively to Prostate-Specific Membrane Antigen and Inhibits its Enzymatic Activity

Prostate-Specific Membrane Antigen (PSMA) targeted prodrug “smartbombs” as therapy for prostate cancer

Development and characterization of prostate specific antigen inhibitors

PSA-activated proaerolysin as a prostate specific cancer therapy

Tumoricidal effects of a PSA-activated pore-forming toxin

Prostate Specific Membrane Antigen (PSMA): A prodrug target for prostate cancer

Nanoparticles as novel vectors for targeted drug delivery to prostate cancer

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only